Elraglusib is a Class-Leading GSK-3β Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer TrialsOrphan Drug Designation...
Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitorOS of...
Expanding Impact to Connect Healthcare Companies and Their Most Important Audiences PHILADELPHIA, Sept. 10, 2024 /PRNewswire/ -- Health Union, the...
CLEVELAND, Sept. 10, 2024 /PRNewswire/ -- September 4th, 2024. GenomOncology, a leading provider of precision medicine software, and Precipio, a...
Former Carevive CEO brings 25 years of experience in life sciences, healthcare technology solutions, data science, and analytics to data...
New tech-enabled services empower pharmaceutical companies to optimize biospecimen operations and data management, transforming sample data into actionable insights RICHMOND,...
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully...
New ResMed-supported research presented at ERS 2024 projects future Chronic Obstructive Pulmonary Disease (COPD) burden in Western Europe, accounting for...
BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+™ in prostate cancerThe...
MORRISTOWN, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment...
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
PRESS RELEASE CHARM Therapeutics appoints Dr Beverley Carr as Chief Business Officer Highly experienced dealmaker to lead CHARM’s business development...
Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians...
Thomas brings more than 20 years of commercial and operations experience in the biopharmaceutical industry to Tonix Tonix is on...
Study demonstrates that TransCode’s lead therapeutic candidate, TTX-MC138, reduces tumor cell capacity for self-renewalBOSTON, Sept. 10, 2024 (GLOBE NEWSWIRE) --...
- Statistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk ratio from DUBLIN-3 Phase 3 Study of Plinabulin plus...
VANCOUVER, BC / ACCESSWIRE / September 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased...
BRIDGEWATER, N.J., Sept. 9, 2024 /PRNewswire/ -- Hamamatsu Photonics K.K. (Hamamatsu City, Japan) has developed a new instrument, creating a unique...
Multi-Institutional Validation Study Highlights the Ability of BelongAI Dave - Cancer Mentor to Accurately Support Cancer Patients NEW YORK, Sept....
Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve...